Sammy

481 posts

Sammy banner
Sammy

Sammy

@ToughSammy

Engineering the future of autonomous pharma factories. Dum Spiro Spero

Katılım Mart 2026
612 Takip Edilen120 Takipçiler
MrBeast
MrBeast@MrBeast·
If this tweet has exactly 1 like in 24 hours I’ll give that person $1,000,000
English
231.4K
25.4K
872.8K
44.1M
Sammy retweetledi
Brett Calhoun
Brett Calhoun@brettcalhounn·
What separates founders who make it: THEY DO NOT GIVE UP. Ever.
English
30
10
176
6.6K
Sammy
Sammy@ToughSammy·
@hthieblot Mustard Biopharma: Smart Manufacturing of Specialized Medicines.
English
0
0
1
11
Hubert Thieblot
Hubert Thieblot@hthieblot·
Describe your product in exactly one sentence. No buzzwords, no fluff, just the core value. If I can’t understand your business in ten seconds, I’m not investing. Hit me & i'll be in your DMs
English
748
4
506
49.6K
Sammy retweetledi
Parmita Mishra
Parmita Mishra@parmita·
those who believed in us early are going to be so incredibly happy they did. that’s what gets me the most excited.
English
1
2
44
934
Sammy
Sammy@ToughSammy·
The more reason @MustardBio is automating Biopharma manufacturing because why the hell should it take 12-18 months for medicines to be manufactured? And why the hell should small batches of medicine cost an arm and a leg 🤔😩
Angus (dirtman)@dirtman

WHY THE HELL DOES IT TAKE A WEEK TO GET A QUOTE FOR AN OFF THE SHELF GEAR THAT THEY HAVE IN STOCK WHY THE FUCK DO I NEED TO WAIT ON A SALES GUY TO SEND IT TO ME WHY THE FUCK IS THERE ONLY ONE MANUFACTURER IN THE USA WHY THE FUCK IS THE LEAD TIME FOR NEW ONES 6 MONTHS

English
0
0
1
22
Sammy
Sammy@ToughSammy·
Hard🔥
English
0
0
1
14
Sammy
Sammy@ToughSammy·
At Mustard Biopharma, we are also fixing Biopharma manufacturing right now. Biopharma manufacturing today is • Slow (12–18 month lead times) • Capital intensive (millions upfront for small batches) • Operationally inefficient (30–40% lost capacity annually) • Fragmented across disconnected factories • Dependent on fragile centralized supply chains
Rodrigo Cortes@RodrigoCorEst

Bio-production has an Engineering problem. We’re fixing it by building the automation layer for biologics to scale. Here are a some insights about Anaula from @RoMcLocko at @DiscipulusVent Demo Day in El Segundo.

English
0
0
1
60
Sammy retweetledi
Dylan Morris
Dylan Morris@Dylan_Morri·
Retweet for no reason at all
Object Zero@Object_Zero_

Turbine Products and Industrial Bottleneck The reason turbines are increasingly becoming an industrial bottleneck is because the only turbine technology that is in mass production today is the hyper-car class of turbine technology, imagine the only car your buy was a Lamborghini, a Bugatti, or a McLaren… that’s where the power turbine market is. Nobody is mass producing the Toyota and Honda class of turbine technology. All turbine product specifications currently in mass production are maximally efficient, and maximally thermodynamically performant. The products available in the market are simply not designed for rapidly scalable production. It’s all single crystalline metallurgy, refractory ceramic coatings and laser drilling. Yes, this stuff is hard to make. No it doesn’t need to be this way. Nobody is still mass producing your grandfather’s turbine. As demand balloons, order books swell, prices surge and lead times are now blowing out to 60 months!… That is more than enough time for a new entrant to come in with a basic, low cost, short lead time mass produced offering that enters the market and quickly captures 40% market share, just by keeping product specs simple enough to scale production capacity horizontally with low lead accessible plant equipment. This is an ironic example of the highest tech sectors needing some low tech solutions. If you see things holistically and you genuinely know what you’re looking at, the world looks different and the solutions to the biggest problems are kind of obvious to you, but this type of observation is just not that common. The real bottleneck in the world is that not many people see the world this way. I guess because it’s such a hard won perspective.

English
1
3
60
3.8K
Sammy
Sammy@ToughSammy·
Spot on, Gaurab. 🔥 Chemicals (especially biopharma manufacturing) are one of the ultimate deeptech arenas right now. At Mustard Biopharma, we are tackling that same brutal intersection, but with an AI-native Factory OS running autonomous mini-factory pods. Unit ops, reaction engineering, fluid dynamics, and real-world application all orchestrated in software so we can produce specialized medicines on-demand, 10x faster and 30x cheaper, even in small batches at the point of need.
Gaurab Chakrabarti@Gaurab

If I were starting a deeptech company today, I'd pick chemicals. Again. Not AI, robotics or space. Because chemicals force you to master four different kinds of engineering problems: 1. Unit operations (mechanical). How to build a physical plant that converts raw materials into product through a sequence of mixing, heating, separating, and purifying steps. We reduced ours from the industry standard of 12 to 20 down to three. That made our plants 5x cheaper to build. 2. Reaction engineering (chemical). I found my first reaction studying pancreatic cancer. The enzyme hit 90% yield versus petrochemical equivalent of 60% for the same reaction. 3. Fluid dynamics (mathematical). A reaction that works in a flask on your bench fails in a 10,000-liter reactor. The flow regime changes, heat transfer breaks down, and dead zones form. Modeling these effects requires data you can only get by operating a real plant. 4. End-molecule chemistry (application). You need to know how your molecule behaves in the customer's actual system. Their water chemistry, reactor conditions, and downstream processes. The molecule isn't the product. It's the molecule working in their system. We started with a $7,000 reactor built with PVC pipes from Home Depot. Last year we shipped 150M lbs of chemicals. Our competitive edge is at the intersection of those four disciplines.

English
0
0
0
29
Sammy
Sammy@ToughSammy·
Biopharma manufacturing is stuck in the 20th century, while the world needs medicines Yesterday, Today, and Tomorrow. Specialized drugs (especially biologics for rare diseases, personalized therapies, or pandemic response) take 12-18 months from raw materials to finished product. Why? Extreme sterility requirements, manual processes, regulatory validation at every step, and massive fixed infrastructure. Mustard Biopharma is building the world’s first AI-native autonomous ‘dark factory’ ecosystem for medicines. Our goal: 10x faster production and up to 30x lower cost, enabling affordable, accessible medicines globally.
Sammy tweet media
English
0
1
2
21